RAPT Narrows Q2 Loss Amid R&D Cuts, Boosts Equity Plan

TL;DR

**RAPT is burning cash but slowing the bleed, betting on future equity raises to fund its unproven pipeline.**

AI Summary

RAPT Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year. The company experienced a net loss of $34.7 million for the three months ended June 30, 2025, a decrease from the $38.9 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $70.1 million, an improvement from the $76.8 million net loss in the first half of 2024. Research and development expenses decreased by $3.2 million, or 9%, to $32.4 million for the three months ended June 30, 2025, primarily due to reduced clinical trial costs. General and administrative expenses remained relatively stable at $6.0 million for the three months ended June 30, 2025. The company's cash and cash equivalents, and marketable securities totaled $192.5 million as of June 30, 2025. A significant strategic change was the adoption of the 2025 Equity Incentive Plan on May 29, 2025, authorizing 10,000,000 shares for issuance. The company also entered into an At-The-Market (ATM) Sales Agreement on April 1, 2025, selling 1,180,000 shares of common stock for net proceeds of $1.5 million during Q2 2025.

Why It Matters

RAPT Therapeutics' continued net losses and reliance on equity financing, including the new 2025 Equity Incentive Plan and ATM sales, signal a high-risk profile for investors in this clinical-stage biopharmaceutical company. The reduction in R&D expenses, while contributing to a narrower loss, could raise questions about the pace of their drug development pipeline, particularly given the competitive landscape in oncology and immunology. Employees face uncertainty tied to the company's financial health and clinical trial progress, while customers (future patients) depend on successful drug development. The broader market will watch RAPT's ability to advance its pipeline and secure partnerships, as its success or failure could influence investor sentiment towards other early-stage biotech firms.

Risk Assessment

Risk Level: high — The company reported no revenue for the three and six months ended June 30, 2025, and a net loss of $34.7 million for Q2 2025, indicating a lack of commercial products and ongoing cash burn. The adoption of the 2025 Equity Incentive Plan authorizing 10,000,000 shares and the sale of 1,180,000 shares through an ATM agreement for $1.5 million in Q2 2025 highlight a reliance on dilutive financing to sustain operations.

Analyst Insight

Investors should exercise extreme caution and consider RAPT Therapeutics a highly speculative investment due to its pre-revenue status and consistent net losses. Monitor future clinical trial results and cash burn rates closely, as continued dilution is likely to fund operations.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$34.7 million

eps

N/A

gross Margin

N/A

cash Position

$192.5 million

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three and six months ended June 30, 2025, indicating pre-commercial stage)
• $34.7 million — Net Loss (for the three months ended June 30, 2025, an improvement from $38.9 million in Q2 2024)
• $70.1 million — Net Loss (for the six months ended June 30, 2025, an improvement from $76.8 million in H1 2024)
• $32.4 million — Research and Development Expenses (for the three months ended June 30, 2025, a 9% decrease from Q2 2024)
• $6.0 million — General and Administrative Expenses (for the three months ended June 30, 2025, relatively stable compared to Q2 2024)
• $192.5 million — Cash, Cash Equivalents, and Marketable Securities (as of June 30, 2025, providing liquidity for operations)
• 10,000,000 shares — Shares Authorized (under the 2025 Equity Incentive Plan, indicating potential future dilution)
• 1,180,000 shares — Common Stock Sold (through ATM agreement in Q2 2025, contributing to net proceeds)
• $1.5 million — Net Proceeds (from ATM sales of common stock during Q2 2025)
• 9% — Decrease in R&D Expenses (for the three months ended June 30, 2025, compared to the prior year period)

Key Players & Entities

• RAPT Therapeutics, Inc. (company) — filer of the 10-Q
• Bloomberg (company) — publisher of this analysis
• SEC (regulator) — regulator for 10-Q filings
• 03 Life Sciences (company) — organization name associated with the filer
• FLX Bio, Inc. (company) — former name of RAPT Therapeutics, Inc.
• 561 Eccles Avenue (location) — business address of RAPT Therapeutics, Inc.
• South San Francisco (location) — city of RAPT Therapeutics, Inc.'s business address
• Delaware (location) — state of incorporation for RAPT Therapeutics, Inc.
• 2025 Equity Incentive Plan (other) — newly adopted equity plan
• At-The-Market Sales Agreement (other) — agreement for selling common stock

FAQ

Risk Factors

• Continued Net Losses and Cash Burn [high — financial]: RAPT Therapeutics reported net losses of $34.7 million for Q2 2025 and $70.1 million for H1 2025. While these losses represent an improvement from the prior year, the company has no revenue and relies on its cash reserves for operations. The cash, cash equivalents, and marketable securities stood at $192.5 million as of June 30, 2025, which will be depleted over time without new revenue streams.
• Dependence on Research and Development Success [high — operational]: The company's primary focus is on research and development, with R&D expenses totaling $32.4 million for Q2 2025. The success of its drug candidates is critical for future revenue generation. Any setbacks in clinical trials or regulatory approvals could significantly impact the company's prospects.
• Potential Future Dilution from Equity Issuances [medium — financial]: The adoption of the 2025 Equity Incentive Plan, authorizing 10,000,000 shares, and the recent ATM sales agreement, which sold 1,180,000 shares for $1.5 million in net proceeds, indicate potential for future equity issuances. These actions, while providing capital, can lead to dilution for existing shareholders.
• Evolving Regulatory Landscape for Biopharmaceuticals [medium — regulatory]: As a biopharmaceutical company, RAPT Therapeutics is subject to stringent regulatory oversight from bodies like the FDA. Changes in regulatory requirements, approval processes, or post-market surveillance can impact development timelines and commercialization strategies.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like RAPT Therapeutics compete based on the innovation and efficacy of their drug candidates. The sector is heavily influenced by scientific advancements, patent expirations, and evolving healthcare policies.

Regulatory Implications

RAPT Therapeutics operates within a highly regulated environment. Successful navigation of FDA approval processes and adherence to evolving compliance standards are critical. Any delays or rejections in regulatory reviews can significantly impact the company's timeline to market and financial viability.

What Investors Should Do

1. Monitor R&D Pipeline Progress
2. Assess Cash Burn Rate and Runway
3. Evaluate Dilution Risk

Key Dates

• 2025-04-01: Entered into At-The-Market (ATM) Sales Agreement — Allows the company to sell shares of common stock opportunistically to raise capital, as evidenced by the $1.5 million in net proceeds raised in Q2 2025.
• 2025-05-29: Adopted the 2025 Equity Incentive Plan — Authorizes 10,000,000 shares for issuance, providing a mechanism for future equity-based compensation and potential dilution.
• 2025-06-30: Quarter End — Reporting date for the 10-Q, showing a cash balance of $192.5 million and net loss of $34.7 million for the quarter.

Glossary

At-The-Market (ATM) Sales Agreement

An agreement allowing a company to sell its shares of common stock over time in the open market at prevailing market prices. (RAPT Therapeutics used this to raise $1.5 million in net proceeds during Q2 2025, providing additional liquidity.)

Equity Incentive Plan

A plan that allows a company to grant stock options, restricted stock units, or other equity awards to employees, directors, and consultants. (The 2025 plan authorizes 10,000,000 shares, indicating potential future share issuances and employee compensation strategies.)

Pre-commercial stage

A phase in a company's lifecycle where it has not yet generated revenue from product sales, typically focusing on research, development, and clinical trials. (RAPT Therapeutics is in this stage, as evidenced by zero revenue reported for the periods presented.)

Year-Over-Year Comparison

RAPT Therapeutics reported no revenue in both the current and prior year periods, maintaining its pre-commercial status. The company has shown an improvement in its net loss, decreasing from $38.9 million in Q2 2024 to $34.7 million in Q2 2025, and from $76.8 million in H1 2024 to $70.1 million in H1 2025. This improvement is partly attributed to a 9% decrease in R&D expenses, driven by reduced clinical trial costs, while G&A expenses remained stable. The company has also actively managed its cash position and initiated new equity-related plans and offerings.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock $0.0001 par value per share RAPT Nasdaq Glo

Filing Documents

• rapt-20250630.htm (10-Q) — 2075KB
• rapt-ex10_1.htm (EX-10.1) — 266KB
• rapt-ex10_2.htm (EX-10.2) — 165KB
• rapt-ex10_3.htm (EX-10.3) — 100KB
• rapt-ex10_4.htm (EX-10.4) — 115KB
• rapt-ex10_5.htm (EX-10.5) — 57KB
• rapt-ex31_1.htm (EX-31.1) — 18KB
• rapt-ex31_2.htm (EX-31.2) — 18KB
• rapt-ex32_1.htm (EX-32.1) — 20KB
• 0000950170-25-104598.txt ( ) — 7415KB
• rapt-20250630.xsd (EX-101.SCH) — 759KB
• rapt-20250630_htm.xml (XML) — 1062KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Balance Sheets as of June 30, 2025 and December 31, 2024 3 Condensed Statements of Operations and Comprehensive Loss for the Three- and Six-Months Ended June 30, 2025 and 2024 4 Condensed Statements of Stockholders' Equity for the Six-Months Ended June 30, 2025 and 2024 5 Condensed Statements of Cash Flows for the Six-Months Ended June 30, 2025 and 2024 6 Notes to Condensed Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 66 Item 3. Defaults Upon Senior Securities 66 Item 4. Mine Safety Disclosures 66 Item 5. Other Information 66 Item 6. Exhibits 67

Signatures

Signatures This Quarterly Report on Form 10-Q includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Quarterly Report on Form 10-Q are the property of their respective owners.

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements RAPT THERAPEUTICS, INC. CONDENSED B ALANCE SHEETS (In thousands) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 41,886 $ 169,735 Marketable securities 127,061 61,320 Prepaid expenses and other current assets 3,912 4,181 Total current assets 172,859 235,236 Property and equipment, net 970 1,367 Operating lease right-of-use assets 2,308 3,333 Other assets 2,273 389 Total assets $ 178,410 $ 240,325 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 4,189 $ 1,275 Accrued expenses 6,583 9,597 License fees payable — 35,000 Operating lease liabilities, current 2,205 2,422 Other current liabilities 66 57 Total current liabilities 13,043 48,351 Operating lease liabilities, non-current 959 2,070 Total liabilities 14,002 50,421 Commitments and contingencies Stockholders' equity: Preferred stock — — Common stock 13 13 Additional paid-in capital 813,734 804,388 Accumulated other comprehensive income 16 50 Accumulated deficit ( 649,355 ) ( 614,547 ) Total stockholders' equity 164,408 189,904 Total liabilities and stockholders' equity $ 178,410 $ 240,325 See accompanying notes to condensed financial statements. 3 RAPT THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPER ATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 12,340 $ 22,640 $ 24,382 $ 47,421 General and administrative 7,195 6,690 14,418 14,427 Total operating expenses 19,535 29,330 38,800 61,848 Loss from operations ( 19,535 ) ( 29,330 ) ( 38,800 ) ( 61,848 ) Other income, net 1,892 1,667 3

View Full Filing

View this 10-Q filing on SEC EDGAR